Patents Examined by Kahsay Habte
  • Patent number: 11186554
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 30, 2021
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Patent number: 11186592
    Abstract: The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 30, 2021
    Assignee: Merck Patent GmbH
    Inventors: Eva-Maria Tanzer, Kai Schiemann, Markus Klein
  • Patent number: 11186568
    Abstract: Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): wherein at least one of R1a to R9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): R10amSH??(i-1) R11anSR12a—SpR13a??(i-2) wherein R10a to R12a each represent a divalent hydrocarbon group or the like; and R13a represents a monovalent hydrocarbon group or the like.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: November 30, 2021
    Assignees: MIYOSHI OIL & FAT CO., LTD., TOKAI OPTICAL CO., LTD.
    Inventors: Koji Kawai, Kotaro Kaneko, Nobuhiro Kaneko, Yuichi Shishino, Kuniyoshi Okamoto
  • Patent number: 11173149
    Abstract: Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDIA3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: November 16, 2021
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, Maria Gabriella Santoro
  • Patent number: 11168075
    Abstract: Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 9, 2021
    Assignee: Acquist LLC
    Inventors: John J. Piwinski, Ronald N. Buckle, Alexandre Larivée, Arshad Siddiqui, Raymond P. Warrell, Jr.
  • Patent number: 11161856
    Abstract: Provided herein are compounds of the formula: and compositions comprising the same, which are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 2, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, Olivia D. Weber, Daniel J. Buzard, Michael B. Shaghafi
  • Patent number: 11154563
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 26, 2021
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Patent number: 11155566
    Abstract: The present invention relates to 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: October 26, 2021
    Inventors: Laurent Provins, Hugues Chanteux
  • Patent number: 11155564
    Abstract: The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 26, 2021
    Inventors: Laurent Provins, Hugues Chanteux
  • Patent number: 11155540
    Abstract: A sulfurized benzoxazine compound, which is usable for the synthesis of a polybenzoxazin, corresponds to formula (A): in which: each benzene nucleus of the two oxazine rings bears at least one radical denoted as “G”; the two oxazine rings are connected together via a central aromatic group, the benzene ring of which bears one, two, three or four groups of formula —Sx—R in which “x” is an integer from 1 to 8 and R represents hydrogen or a hydrocarbon-based group including 1 to 10 carbon atoms and optionally a heteroatom chosen from O, S, N and P; and the at least two radicals G, which may be identical or different, are chosen from various groups.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 26, 2021
    Assignee: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
    Inventors: Milan Fedurco, Marco Ribezzo
  • Patent number: 11155565
    Abstract: The present invention relates to 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 26, 2021
    Inventors: Laurent Provins, Hugues Chanteux, Yannick Quesnel
  • Patent number: 11142534
    Abstract: The present invention relates to a process for synthesizing a compound of formula (I), R1 is H or C1-6alkyl; R2 is H or hydroxy; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: October 12, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Junli Chen, Manuel Konrath, Roland Meier, Yan Ren, Xuemei Wang, Jing Xiong, Jianhua Yu
  • Patent number: 11142507
    Abstract: The present invention provides novel compounds of Formulae (I?), (I), (II?), and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 12, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski, Mingfeng Hao
  • Patent number: 11136615
    Abstract: Disclosed herein are compositions and methods for stabilizing a benzothiazole luciferin analog such as D-luciferin and 6-amino-D-luciferin. The compositions may include the benzothiazole luciferin analog, a thionucleobase compound of formula (I), and a liquid medium, in which the thionucleobase is present in an amount effective to stabilize the luminogenic composition against decomposition. The methods provided herein may stabilize the benzothiazole luciferin analog against decomposition by contacting the benzothiazole luciferin analog with an effective amount of the thionucleobase compound in the presence of a liquid medium. Also provided herein is a kit containing the composition.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 5, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Ce Shi, Mary P. Hall, Thomas A. Kirkland, Lance P. Encell, Poncho Meisenheimer, Wenhui Zhou
  • Patent number: 11129838
    Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 28, 2021
    Assignee: Unity Biotechnology, Inc.
    Inventors: Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
  • Patent number: 11123722
    Abstract: This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: September 21, 2021
    Assignees: California Institute of Technology
    Inventors: Adam M. Johns, Jessica R. Herron, Richard L. Pederson, Bryan A. Fiamengo, Jennifer A. Beerman, Tzu-Pin Lin, Crystal K. Chu, Robert H. Grubbs
  • Patent number: 11124537
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 21, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
  • Patent number: 11117881
    Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 14, 2021
    Assignee: LANDOS BIOPHARMA, INC.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
  • Patent number: 11116772
    Abstract: This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: September 14, 2021
    Assignee: WisTa Laboratories Ltd.
    Inventors: John Mervyn David Storey, James Peter Sinclair, Colin Marshall, Han Wan Tan, Claude Michel Wischik
  • Patent number: 11111237
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: September 7, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Yong Je Shin, Jin Hee Kim, Jun Lee, Sook Kyung Park, Ho Yeon Lee, Hyun Suk Choi, Se Hyuk Kim, Eun Ji Kang, Ho Youl Lee, Soo Yeon Jung